My passion is company formation and building life science technologies and platforms. My specialty is a keen focus on business development to bring products to market directly and with major biotech, pharma and cell & gene therapy companies.

About BioMagnetic Solutions:
Founded in in 2012, BioMagnetic Solutions manufactures magnetic cell selection reagents and systems for CAR-T cell & gene therapy product manufacture that will be cGMP in Q4:22. The market for clinical magnetic cell selection will reach $1.2 billion by 2030. In 2022, BioMagnetic Solutions introduces our FerroSelect™ clinical-scale cell selection system for CAR-T cell & gene therapy product manufacture. FerroSelect™ is a faster, easier to use and highly adaptable cell selection system for process development and GMP CAR-T/GT manufacturing groups.

In 2022, BioMag's FerroSelect™ Clinical-Scale Cell Selection system will offer an array of cGMP clinical-grade mAbs and Ferofluid magnetic cell selection reagents for CAR-T CGT product manufacture in Q4:22 and Q1:23.

Co-founded by Dr. Paul A. Liberti and Ted L. Liberti in 2011, BioMag is the successor to Immunicon Corp. (NASDAQ: IMMC) where BioMag's founder Dr. Paul A. Liberti developed CELLSEARCH® ~ the only FDA-approved circulating tumor cell (CTC) assay marketed & owned by J&J's Janssen unit & acquired by Menarini’s Silicon BioSystems in 2017. BioMagnetic Solutions brings 30+ years of: innovation, problem-solving, product development, IP & design to BioMag's proprietary Ferrofluids & magnetic cell selection devices for CGT product manufacturing applications.